The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Since the development of vaccinia virus as a vaccine vector in 1984, the utility of numerous
viruses in vaccination strategies has been explored. In recent years, key improvements to …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …

An effective vaccine is needed for the prevention and elimination of malaria. The only
immunogens that have been shown to have a protective efficacy of more than 90% against …

Background Heterologous prime boost immunization with chimpanzee adenovirus 63
(ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy …

Background RH5 is a leading blood-stage candidate antigen for a Plasmodium falciparum
vaccine; however, its safety and immunogenicity in malaria-endemic populations are …

Malaria vaccine development has rapidly advanced in the past decade. The very first phase
3 clinical trial of the RTS, S vaccine was completed with over 15,000 African infants and …

In 2016, there were more cases and deaths caused by malaria globally than in 2015. An
effective vaccine would be an ideal additional tool for reducing malaria's impact. Sanaria® …

Background GMZ2 is a recombinant malaria vaccine inducing immune responses against
Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We …